Scientists discover way of developing test for Parkinson's disease diagnosis

December 7, 2016, University of Texas Health Science Center at Houston
Claudio Soto, Ph.D. Credit: University of Texas Health Science Center at Houston

Misfolded proteins associated with Parkinson's disease were detected in cerebrospinal fluid by scientists at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), paving the way to development of a biochemical test to diagnosis the disease.

The research, led by Claudio Soto, Ph.D., professor in the Department of Neurology and the director of the George and Cynthia Mitchell Center for Alzheimer's disease and Related Brain Disorders at UTHealth, was published in yesterday's issue of JAMA Neurology, a journal of the American Medical Association.

Parkinson's disease (PD) is a of the brain that initially affects motor skills, causing tremors, stiffness, slowness of movement and impaired balance. As it progresses, patients may develop cognitive problems, psychiatric alterations and dementia. There are no current laboratory or blood tests that have been proven to help in diagnosis. Because the disease can be difficult to diagnose accurately, diagnosis is sometimes is made by ruling out other neurological diseases.

Using a technology developed by Soto that was shown in previous studies to detect associated with diseases such as Creutzfeld-Jacob and Alzheimer's disease, researchers targeted misfolded alpha-synuclein (aSyn) aggregates as a way of developing a sensitive biochemical diagnosis for PD. The Protein Misfolding Cyclic Amplification (PMCA) technology was able to detect very small amounts of the misfolded protein circulating in cerebrospinal fluid.

"Of significant interest is that the amount of aSyn detected correlates with the severity of the disease and in two of the control samples, aSyn was detected and those people later developed clinical symptoms of PD," Soto said.

The research included blind screenings of cerebrospinal fluid of two cohorts of 76 PD patients, as well as controls of 65 people who were healthy or affected by other neurological disorders, 18 affected by neurodegenerative diseases and 14 affected by Alzheimer's disease.

Since is removed through spinal taps, which are invasive and painful, the hope is that future research would enable optimization of the PMCA assay to detect aSyn in blood or urine.

"The hope is that we could use aSyn-PMCA to detect PD in patients before they develop symptoms, and those patients could be entered into clinical trials for novel treatments that might prevent, cure or delay the progression of the disease before substantial and irreversible damage of the brain," Soto said.

Explore further: Early detection of Alzheimer's disease made possible by analyzing spinal fluid

More information: Mohammad Shahnawaz et al, Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid, JAMA Neurology (2016). DOI: 10.1001/jamaneurol.2016.4547

Related Stories

Early detection of Alzheimer's disease made possible by analyzing spinal fluid

March 20, 2014
Researchers have shown that they can detect tiny, misfolded protein fragments in cerebrospinal fluid taken from patients. Such fragments have been suggested to be the main culprit in Alzheimer's disease. The findings reported ...

Researchers find infectious prion protein in urine of patients with variant Creutzfeldt-Jakob disease

August 7, 2014
The misfolded and infectious prion protein that is a marker for variant Creutzfeldt-Jakob disease – linked to the consumption of infected cattle meat – has been detected in the urine of patients with the disease by researchers ...

Parkinson's study could pave way for early detection test

August 29, 2016
A test that can detect Parkinson's disease in the early stages of the illness has moved a step closer.

A urine test for Creutzfeldt-Jakob Disease may be possible

October 4, 2016
Researchers at the MRC Prion Unit at UCL have found that it may be possible to determine whether or not a person has sporadic Creutzfeldt-Jakob Disease (sCJD) by testing their urine for the presence of abnormal prion proteins.

Biomarkers in cerebrospinal fluid can identify patients with Alzheimer's disease

October 22, 2012
Analysis of specific biomarkers in a cerebrospinal fluid sample can differentiate patients with Alzheimer's disease from those with other types of dementia. The method, which is being studied by researchers at Sahlgrenska ...

Promising new methods for early detection of Alzheimer's disease

July 8, 2016
New methods to examine the brain and spinal fluid heighten the chance of early diagnosis of Alzheimer's disease. Results from a large European study, led by researchers at the Karolinska Institutet, are now published in the ...

Recommended for you

Growing a brain: Two-step control mechanism identified in mouse stem cells

December 17, 2018
Scientists have identified two distinct control mechanisms in the developmental transition of undifferentiated stem cells into healthy brain cells. This fundamental research using mice may inform regenerative medicine treatments ...

Two compounds in coffee may team up to fight Parkinson's

December 10, 2018
Rutgers scientists have found a compound in coffee that may team up with caffeine to fight Parkinson's disease and Lewy body dementia—two progressive and currently incurable diseases associated with brain degeneration.

New Parkinson's disease drug target revealed through study of fatty acids

December 4, 2018
The human brain is rich in lipids. Investigators studying Parkinson's disease (PD) have become increasingly interested in lipids since both molecular and genetic studies have pointed to the disruption of the balance of the ...

A toxin that travels from stomach to brain may trigger Parkinsonism

December 4, 2018
Combining low doses of a toxic herbicide with sugar-binding proteins called lectins may trigger Parkinsonism—symptoms typical of Parkinson's disease like body tremors and slowing of body motions—after the toxin travels ...

Experimental cancer drug shows promise for Parkinson's

December 3, 2018
The study, funded by Parkinson's UK, suggests that the drug, tasquinimod, which is not yet on the market, works by controlling genes that may cause Parkinson's. This happens when the drug interacts with a protein inside brain ...

Parkinson's therapy creates new brain circuits for motor function, study finds

November 28, 2018
Scientists have uncovered that an emerging gene therapy for Parkinson's disease creates new circuits in the brain associated with improved motor movement. These findings, published today in Science Translational Medicine ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.